Strategic Focus Emerging cancer immunotherapy play centered on macrophage repolarization and tumor microenvironment modulation, signaling potential collaboration opportunities in immuno-oncology drug discovery and development.

Early Stage Potential Late preclinical stage with first-in-class monoclonal antibodies targeting PSGL-1 and VSIG4, indicating opportunities for preclinical partnerships, translational research, and potential alignment with CROs for IND-enabling activities.

Target Discovery Engine Proprietary computational biology platform identifying numerous macrophage targets suggests potential for data/license deals, collaboration on target validation, and joint discovery programs.

Funding & Partnerships Existing $54M funding and past collaborations (e.g., with Sunshine Guojian Pharmaceutical) imply readiness for co-development, milestone-driven partnerships, and international licensing discussions.

NB Tech Stack Small team vehicle with lean operations but modern cloud and collaboration tools; opportunities to offer tailored services, CRO support, and scalable outsourcing arrangements to accelerate go-to-clinic timelines.